Tenofovir DF 300 mg + Lamivudine 300 mg
This fixed-dose combination of two nucleos(t)ide reverse transcriptase inhibitors serves as a foundational component in antiretroviral therapy, contributing to sustained viral suppression in patients with HIV-1 infection when used alongside other recommended agents.
Product Details
Therapeutic Class
Nucleos(t)ide Reverse Transcriptase Inhibitors (Tenofovir DF + Lamivudine)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
One tablet once daily, or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
30 Tablets